Central Serous Chorioretinopathy
Conditions
Brief summary
The pathophysiology of central serous chorioretinopathy remains controversial. traditional treatment is laser photocoagulation or photodynamic therapy.Recently Bevacizumab (Avastin, Genetech),an antibody to vascular endothelial growth factor (VEGF),has known antipermeability properties and therefore may theoretically reverse the changes seen in central serous chorioretinopathy. The aim of this study is To investigate concentrations of growth factors and inflammatory cytokines and to report the effect of therapy with bevacizumab in eyes with central serous chorioretinopathy
Interventions
PROCEDUREintravitreal injection with anterior paracentesis
0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
Sponsors
Hallym University Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of central serous chorioretinopathy * Idiopathic neurosensory retinal elevation demonstrated by optical coherent tomography * Presence of focal leaks at the level of the RPE on fluorescein angiography
Exclusion criteria
* Known side effects of systemic bevacizumab administration * Have a significant cardiovascular or thromboembolic history or were pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentrations of growth factors and inflammatory cytokines in Aqueous humor | at baseline |
Secondary
| Measure | Time frame |
|---|---|
| Central macular thickness at optical coherence tomography | baseline, 1 month, 3 months, 6 months |
Outcome results
None listed